Rezolute, Inc.
(NASDAQ : RZLT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Technology Services » Internet Software Or Services
symbolcompany%chnglast%shortavg$volume
FBFacebook, Inc. 0.16%340.530.7%$7427.27m
GOOGLAlphabet, Inc. -1.03%2835.220.5%$4097.53m
GOOGAlphabet, Inc. -0.96%2848.970.5%$3227.91m
AFRMAffirm Holdings, Inc. -4.04%149.080.0%$2930.71m
UPSTUpstart Holdings, Inc. -1.82%360.390.0%$1781.39m
SNAPSnap, Inc. -1.26%75.472.3%$1302.24m
SESea Ltd. (Singapore) -1.35%362.043.1%$1004.42m
TWTRTwitter, Inc. -0.46%65.818.8%$706.69m
DKNGDraftKings, Inc. 0.46%49.070.0%$663.68m
BIDUBaidu, Inc. 1.71%182.062.3%$635.78m
MELIMercadoLibre, Inc. 0.64%1601.373.6%$588.68m
FUTUFutu Holdings Ltd. 1.11%67.240.0%$462.94m
PINSPinterest, Inc. 13.62%63.150.0%$455.67m
MTCHMatch Group, Inc. -1.18%158.804.3%$442.32m
DASHDoorDash, Inc. 0.94%215.340.0%$401.11m

Company Profile

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.